For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
19
views
71
references
 Top references
cited by
2
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      209
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Performance Evaluation of a Novel Potentiometric Membrane Sensor for Determination of Atorvastatin in Pharmaceutical Preparations

      research-article

      Read this article at

      ScienceOpenPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          A novel potentiometric ion-selective PVC membrane sensor for analysis of atorvastatin (AT) in pharmaceutical preparations based on atorvastatin-(tetraphenyl borate), (AT-(TPB)2) as sensing element, tetraphenyl borate as additive and tris-2-ethyl-hexyl phosphate (TOP) as plasticizer solvent was prepared. The electrode shows a good Nernestian response over the concentration range of 0.09–5586 μg mL -1of AT with slope of 30.1±0.1 mV/decade and limit of detection0.056μg mL -1.The response time of sensor is fats (less than 10 sec) and could be used for about one month in the pH range of 4.5–8.0. The electrode exhibit good selectivity for the AT in the presence of large amount of co-drugs and inorganic cations. The method is precise and accurate with mean relative standard deviation of <2%.Atorvastatin is determined successfully in several tablets by the proposed membrane.

          Related collections

          Most cited references71

          • Record: found
          • Abstract: not found
          • Article: not found

          Carrier-Based Ion-Selective Electrodes and Bulk Optodes. 1. General Characteristics.

          Eric Bakker, Philippe Bühlmann, Ernö Pretsch (1997)
          Article 0 comments Cited 198 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

            S Kafonek, D B Hunninghake, I Laurora … (1998)
            The objective of this multicenter, randomized, open-label, parallel-group, 8-week study was to evaluate the comparative dose efficacy of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor atorvastatin 10, 20, 40, and 80 mg compared with simvastatin 10, 20, and 40 mg, pravastatin 10, 20, and 40 mg, lovastatin 20, 40, and 80 mg, and fluvastatin 20 and 40 mg. Investigators enrolled 534 hypercholesterolemic patients (low-density lipoprotein [LDL] cholesterol > or = 160 mg/dl [4.2 mmol/L] and triglycerides < or = 400 mg/dl [4.5 mmol/L]). The efficacy end points were mean percent change in plasma LDL cholesterol (primary), total cholesterol, triglycerides, and high-density lipoprotein cholesterol concentrations from baseline to the end of treatment (week 8). Atorvastatin 10, 20, and 40 mg produced greater (p < or = 0.01) reductions in LDL cholesterol, -38%, -46%, and -51%, respectively, than the milligram equivalent doses of simvastatin, pravastatin, lovastatin, and fluvastatin. Atorvastatin 10 mg produced LDL cholesterol reductions comparable to or greater than (p < or = 0.02) simvastatin 10, 20, and 40 mg, pravastatin 10, 20, and 40 mg, lovastatin 20 and 40 mg, and fluvastatin 20 and 40 mg. Atorvastatin 10, 20, and 40 mg produced greater (p < or = 0.01) reductions in total cholesterol than the milligram equivalent doses of simvastatin, pravastatin, lovastatin, and fluvastatin. All reductase inhibitors studied had similar tolerability. There were no incidences of persistent elevations in serum transaminases or myositis.
            Article 0 comments Cited 64 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor.

              H L Haber, Aaron D. Black, Patricia M. Davidson … (1995)
              This 6-week, double-blind clinical trial evaluated lipid parameter responses to different dosages of atorvastatin in patients with primary hypercholesterolemia. Atorvastatin is a new 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor under development. After completing an 8-week placebo-baseline dietary phase, 81 patients were randomly assigned to receive either placebo or 2.5, 5, 10, 20, 40, or 80 mg atorvastatin once daily for 6 weeks. Plasma LDL cholesterol reductions from baseline were dose related, with 25% to 61% reduction from the minimum dose to the maximum dose of 80 mg atorvastatin once a day. Plasma total cholesterol and apo B reductions were also dose related. Previously, reductions in LDL cholesterol of the magnitude observed in this study have been seen only with combination drug therapy. In this study, atorvastatin was well tolerated by hyperlipidemic patients, had an acceptable safety profile, and provided greater reduction in cholesterol than other previously reported HMG-CoA reductase inhibitors.
              Article 0 comments Cited 43 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (nlm-ta): Iran J Pharm Res
                Journal ID (iso-abbrev): Iran J Pharm Res
                Journal ID (publisher-id): IJPR
                Title: Iranian Journal of Pharmaceutical Research : IJPR
                Publisher: Shaheed Beheshti University of Medical Sciences (Tehran, Iran )
                ISSN (Print): 1735-0328
                ISSN (Electronic): 1726-6890
                Publication date (Print): Autumn 2013
                Volume: 12
                Issue: 4
                Pages: 645-657
                Affiliations
                [a ] Drug Delivery Research Center, Faculty of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Islamic Republic of Iran.
                [b ] Department of Medicinal Chemistry, Faculty of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Islamic Republic of Iran.
                Author notes
                [* ]Corresponding author: E-mail: fahmadi@kums.ac.ir
                Article
                Publisher ID: ijpr-12-645
                PMC ID: 3920707
                PubMed ID: 24523744
                SO-VID: 1dd89b88-be28-40fd-8e38-6287b74f93a7
                Copyright © © 2013 by School of Pharmacy, Shaheed Beheshti University of Medical Sciences and Health Services
                License:

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License, ( http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                Date received : June 2012
                Date accepted : August 2013
                Categories
                Subject: Original Article

                Keywords: atorvastatin,pvc membrane,potentiometric sensor,analysis of pharmaceutical preparation
                Data availability:
                Keywords: atorvastatin, pvc membrane, potentiometric sensor, analysis of pharmaceutical preparation

                Comments

                Comment on this article

                Similar content209

                See all similar

                Cited by1

                See all cited by

                Most referenced authors294

                See all reference authors